News

Merck cooperates with Symphogen
Enlarge image

BusinessGermanyDenmark

Merck cooperates with Symphogen

07.09.2012 - German Merck KGaA enters a license deal worth up to €495m with Danish Symphogen to receive exclusive rights to a Phase II cancer drug

Symphogen's Sym004 is a recombinant IgG1 antibody product consisting of two antibodies targeting the epidermal growth factor receptor (EGFR). It is currently being evaluated in a Phase I/II trial for the treatment of patients with advanced KRAS wild-type metastatic colorectal cancer (mCRC) as a second-line treatment. In addition, a single-arm, open-label Phase II trial is on-going in patients with squamous cell carcinoma of the head and neck (SCCHN) who have failed anti-EGFR-based therapy.

Under the terms of the agreement, Merck will pay Symphogen €20m upfront. The Danish antibody specialist is also eligible to receive up to €225m for clinical development and regulatory milestones, €250m in potential combined sales performance milestones as well as royalties on net worldwide sales. In exchange, Merck will gain exclusive worldwide rights to develop and commercialise Sym004. 

Sym004 is designed to block ligand binding, receptor activation and downstream signalling. The antibodies are also thought to elicit removal of the EGFR receptors from the cancer cell surface by inducing EGFR internalisation and degradation. Merck says it sees the program as a natural extension of its Erbitux franchise.

The German pharma giant has come under pressure lately, as important R&D projects, like the oral MS treatment Cladribine, failed. In the wake of the setbacks, it decided to start a major restructuring programme. Merck decided to close down its Merck Serono headquarter in Geneva and lately announced to lay off 1,100 employees in Germany.

http://www.european-biotechnology-news.com/news/news/2012-03/merck-cooperates-with-symphogen.html

SurveyGermany

06.05.2015 More revenue, more staff, more funding: in the German biotech industry, all signs are pointing towards growth.

M&ASwitzerland

04.05.2015 Swiss crop chemical maker Syngenta AG is in talks with US company Monsanto to discuss a possible merger, insiders say.

BiofuelsEU

30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.

FinancingSwitzerlandUK

29.04.2015 Biopharma start-up CRISPR Therapeutics has raised US$64m to hurry the new CRISPR/Cas9 technology to the clinic.

FinancingBelgium

28.04.2015 After having raised €100m in its stock market debut, MDx company Biocartis has gained 13 percent on its first trading day.

Swiss Biotech DaySwitzerland

16.04.2015 The Swiss biotech industry can look back on 2014 as a good year, but political uncertainties do remain. This was one of the topics discussed during the Swiss Biotech Day in Basel, which attracted more than 400 participants.

FinancingUK

21.04.2015 Ahead of its listing on the London Stock Exchange, Woodford’s Patient Capital Trust has raised a record sum of €1.1bn. The fund met with immense interest by investors.

PoliticsEU

22.04.2015 A legislative proposal by the European Commission is set to renationalise market authorisation of genetically modified crops.

EventEUFrance

16.04.2015 The changing landscape in healthcare was just one of the hotly discussed topics of the 27th Annual EuroMeeting of the international association DIA.

R&DFranceUKSweden

24.04.2015 AstraZeneca has boosted its oncology portfolio by signing a US$1.275bn agreement with Innate Pharma. The companies plan to further the development of Innate’s tumour-targeting antibody.

Events

All Events

Partner-Events

München

BioVaria 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • 4SC5.41 EUR4.04%
  • WILEX5.25 EUR3.35%
  • BIOFRONTERA2.34 EUR1.74%

FLOP

  • VITA 345.86 EUR-6.69%
  • FORMYCON26.31 EUR-6.04%
  • MORPHOSYS63.42 EUR-6.02%

TOP

  • 4SC5.41 EUR322.7%
  • WILEX5.25 EUR83.6%
  • PAION2.85 EUR21.3%

FLOP

  • BIOTEST72.00 EUR-25.9%
  • THERAMETRICS0.07 CHF-22.2%
  • MEDIGENE10.16 EUR-17.6%

TOP

  • SANTHERA96.00 CHF2361.5%
  • CYTOS1.27 CHF647.1%
  • WILEX5.25 EUR517.6%

FLOP

  • MOLOGEN4.85 EUR-55.5%
  • THERAMETRICS0.07 CHF-30.0%
  • BIOFRONTERA2.34 EUR-26.6%

No liability assumed, Date: 05.05.2015